Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

Objective:To determine the safety and effectiveness of BufferGel and 0.5% PRO2000 microbicide gels for the prevention of male-to-female HIV transmission. Design:Phase II/IIb, randomized, placebo-controlled trial with three double-blinded gel arms and an open-label no gel arm. Methods:Study participants from Malawi, South Africa, Zambia, Zimbabwe, and the USA were instructed to apply study gel up to 1 h before each sex act and safety, sexual behavior, pregnancy, gel adherence, acceptability, and HIV serostatus were assessed during follow-up. Results:The 3101 enrolled women were followed for an average of 20.4 months with 93.6% retention and 81.1% self-reported gel adherence. Adverse event rates were similar in all study arms. HIV incidence rates in the 0.5% PRO2000 gel, BufferGel, placebo gel, and no gel arms were 2.70, 4.14, 3.91, and 4.02 per 100 women-years, respectively. HIV incidence in the 0.5% PRO2000 gel arm was lower than the placebo gel arm (hazard ratio = 0.7, P = 0.10) and the no gel arm (hazard ratio = 0.67, P = 0.06). HIV incidence rates were similar in the BufferGel and both placebo gel (hazard ratio = 1.10, P = 0.63) and no gel control arms (hazard ratio = 1.05, P = 0.78). HIV incidence was similar in the placebo gel and no gel arms (hazard ratio = 0.97, P = 0.89). Conclusion:The 0.5% PRO2000 gel demonstrated a modest 30% reduction in HIV acquisition in women. However, these results were not statistically significant and subsequent findings from the Microbicide Development Programme (MDP) 301 trial have confirmed that 0.5% PRO2000 gel has little or no protective effect. BufferGel did not alter the risk of HIV infection. Both products were well tolerated.

[1]  J. H. van de Wijgert,et al.  Phase 1 Trial of the Topical Microbicide BufferGel: Safety Results From Four International Sites , 2001, Journal of acquired immune deficiency syndromes.

[2]  R. Connor.  Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH. , 2006, Journal of acquired immune deficiency syndromes.

[3]  C. Caceres,et al.  HIV/AIDS in Latin America and the Caribbean: an update , 1996, AIDS.

[4]  L. van Damme,et al.  A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. , 2000, Sexually transmitted infections.

[5]  Michel Alary,et al.  Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. , 2008, The New England journal of medicine.

[6]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[7]  D. Jeffries,et al.  `Chemical condoms’ for the prevention of HIV infection: evaluation of novel agents against SHIV89.6PDin vitro and in vivo , 2001, AIDS.

[8]  S. Lagakos,et al.  Methodological challenges in biomedical HIV prevention trials. , 2008 .

[9]  H. Rees,et al.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial , 2002, The Lancet.

[10]  U. Tamoufé,et al.  Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. , 2002, JAMA.

[11]  S. Hillier,et al.  Limitations of the Dye-Based Method for Determining Vaginal Applicator Use in Microbicide Trials , 2009, Sexually transmitted diseases.

[12]  J. Peipert,et al.  Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Smita,et al.  Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India , 2006, AIDS research and therapy.

[14]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[15]  A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. , 1999, The New England journal of medicine.

[16]  S. S. Olmsted,et al.  Tests of BufferGel for Contraception and Prevention of Sexually Transmitted Diseases in Animal Models , 2001, Sexually transmitted diseases.

[17]  P. Feldblum,et al.  SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria , 2008, PloS one.

[18]  L. Heise,et al.  Challenges for the development of female-controlled vaginal microbicides. , 1994, AIDS.

[19]  B. Friedland,et al.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[20]  C. Coggins,et al.  Female-controlled methods to prevent sexual transmission of HIV. , 1996, AIDS.

[21]  S. Karim,et al.  PRO 2000: next steps for microbicide development , 2009 .

[22]  K. Mayer,et al.  Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. , 2000, Family planning perspectives.

[23]  S. S. Olmsted,et al.  Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model , 2005, BMC infectious diseases.

[24]  B. Richardson,et al.  Evaluation of a Low-Dose Nonoxynol-9 Gel for the Prevention of Sexually Transmitted Diseases: A Randomized Clinical Trial , 2001, Sexually transmitted diseases.

[25]  S. Dandekar,et al.  Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques , 1994, AIDS.

[26]  T. Fleming,et al.  Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. , 1992, JAMA.

[27]  G. Doncel,et al.  In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. , 2005, AIDS research and human retroviruses.

[28]  S. Weller,et al.  The effectiveness of condoms in reducing heterosexual transmission of HIV. , 1999, Family planning perspectives.

[29]  Thomas R Fleming,et al.  Some design issues in trials of microbicides for the prevention of HIV infection. , 2004, The Journal of infectious diseases.

[30]  S. S. Olmsted,et al.  The rate at which human sperm are immobilized and killed by mild acidity. , 2000, Fertility and sterility.

[31]  H. Rees,et al.  Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women , 2003, AIDS.

[32]  J. Wijgert,et al.  Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. , 2001 .

[33]  Sheena McCormack,et al.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial , 2010, The Lancet.